Maleisië - Engels - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glenmark pharmaceuticals (malaysia) sdn. bhd. - apremilast -

Maleisië - Engels - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glenmark pharmaceuticals (malaysia) sdn. bhd. - apremilast -

Ierland - Engels - HPRA (Health Products Regulatory Authority)

glenmark arzneimittel gmbh - levocetirizine dihydrochloride - film-coated tablet - 5 milligram(s) - piperazine derivatives; levocetirizine

Ierland - Engels - HPRA (Health Products Regulatory Authority)

glenmark pharmaceuticals europe limited - riluzole - film coated tablet - 50 milligram

Ierland - Engels - HPRA (Health Products Regulatory Authority)

glenmark generics (europe) ltd - perindopril tert-butylamine indapamide - tablets - 2/0.625 milligram

Ierland - Engels - HPRA (Health Products Regulatory Authority)

glenmark generics (europe) ltd - perindopril tert-butylamine indapamide - tablets - 4/1.25 milligram

Europese Unie - Engels - EMA (European Medicines Agency)

glenmark arzneimittel gmbh - olanzapine - schizophrenia; bipolar disorder - psycholeptics - adultsolanzapine is indicated for the treatment of schizophrenia.olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.olanzapine is indicated for the treatment of moderate to severe manic episode. in patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.

Europese Unie - Engels - EMA (European Medicines Agency)

glenmark arzneimittel gmbh - olanzapine - schizophrenia; bipolar disorder - psycholeptics - adultsolanzapine is indicated for the treatment of schizophrenia.olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.olanzapine is indicated for the treatment of moderate to severe manic episode. in patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.

Verenigde Staten - Engels - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - zonisamide (unii: 459384h98v) (zonisamide - unii:459384h98v) - zonisamide 25 mg - zonisamide capsules are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. zonisamide capsules are contraindicated in patients who have demonstrated hypersensitivity to sulfonamides or zonisamide. the abuse and dependence potential of zonisamide has not been evaluated in human studies (see warnings, cognitive/neuropsychiatric adverse events subsection). in a series of animal studies, zonisamide did not demonstrate abuse liability and dependence potential. monkeys did not self-administer zonisamide in a standard reinforcing paradigm. rats exposed to zonisamide did not exhibit signs of physical dependence of the cns-depressant type. rats did not generalize the effects of diazepam to zonisamide in a standard discrimination paradigm after training, suggesting that zonisamide does not have abuse potential of the benzodiazepine-cns depressant type.

Verenigde Staten - Engels - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - marlissa® (levonorgestrel and ethinyl estradiol tablets) is indicated for use by females of reproductive potential to prevent pregnancy. marlissa® (levonorgestrel and ethinyl estradiol tablets) is contraindicated in females who are known to have the following conditions:                                                               marlissa® (mĀr-lis-sĂ)                              (levonorgestrel and ethinyl estradiol tablets, usp 0.15 mg/0.03 mg) important information about taking marlissa® (levonorgestrel and ethinyl estradiol tablets) before you start taking marlissa® (levonorgestrel and ethinyl estradiol tablets): when should i start taking marlissa® (levonorgestrel and ethinyl estradiol tablets)? if you start taking marlissa® (levonorgestrel and ethinyl estradiol tablets) and you have not used a hormonal birth control method before: if you start taking marlissa® (levonorgestrel and ethinyl estradiol tablets) and you are switching from another birth control pill: if you start taking marlissa® (levonorgestrel and ethinyl estradiol tablets) and previously used a vaginal ring: if you start taking marlissa® (levonorgestrel and ethinyl estradiol tablets) and previously used a transdermal patch: if you start taking marlissa® (levonorgestrel and ethinyl estradiol tablets) and you are switching from a progestin-only method such as an implant or injection: if you start taking marlissa® (levonorgestrel and ethinyl estradiol tablets) and you are switching from an intrauterine device or system (iud or ius): keep a calendar to track your period: if this is the first time you are taking birth control pills, read, “when should i start taking marlissa® (levonorgestrel and ethinyl estradiol tablets)? ” above. follow these instructions for either a sunday start or a day 1 start . instructions for using your marlissa® (levonorgestrel and ethinyl estradiol tablets) pill dispenser: sunday start: you will use a sunday start if your healthcare provider told you to take your first pill on a sunday. day 1 start: you will use a day 1 start if your doctor told you to take your first pill (day 1) on the first day of your period . what should i do if i miss any marlissa® (levonorgestrel and ethinyl estradiol tablets) pills? if you miss 1 pill in weeks 1, 2, or 3, follow these steps: if you miss 2 pills in week 1 or week 2 of your pack, follow these steps: if you miss 2 pills in a row in week 3, or you miss 3 or more pills in a row during weeks 1, 2, or 3 of the pack, follow these steps: if you have any questions or are unsure about the information in this leaflet, call your healthcare provider. this patient information and instructions for use have been approved by the u.s. food and drug administration. manufactured by: glenmark pharmaceuticals limited colvale-bardez, goa 403513, india manufactured for: glenmark pharmaceuticals inc., usa mahwah, nj 07430 questions? 1 (888) 721-7115 www.glenmarkpharma-us.com june 2022